Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, real and recurring, early stage. In the transcript, Cathy Zoi mentions the GM-Pilot partnership: "this collaboration with GM and Pilot Company, we announced an EVgo extend product to deploy up to 2,000 charging stalls and up to 500 pilot and Flying J locations across the United States." She says "This GM-Pilot partnership represents the first major announcement of the EVgo eXtend offering we highlighted earlier this year." So it's the first major one. But is there a comparison to past deals? She says "Our history and track record in operating complex public fast charging networks with higher liability positions EVgo as the ideal partner." Not about size escalation. Olga discusses the eXtend model vs core model. She says "In the eXtend model, EviGo sees positive cash flow immediately." But no comparison of deal sizes. Cathy mentions "we also recently announced a charging partnership with the City of Philadelphia" and "a managed charging pilot program with a major Midwestern investor owned utility" - but no size comparison. She mentions "we entered into a charger supply agreement with Delta electronics. Under the terms and disagreement EVgo will purchase more than 1,000 chargers, which equates to 2,000 EV charging stalls." That's a supply agreement, not a customer deal. Is there any statement that deals are getting bigger? Possibly the Pilot deal is large, but is it presented as part of an upward drift? Cathy says "This GM-Pilot partnership represents the first major announcement of the EVgo eXtend offering" - so it's the first, not a pattern. She doesn't say that previous deals were smaller and now they are bigger. She says "EVgo eXtend partnerships provide for increased growth opportunities" but no comparison. Also, the question asks about "successive engagements of the same kind" - meaning the same offering. The eXtend offering is new, so this is the first one. No evidence of escalation. Look for any mention of average deal size increasing. Not present. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.